March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 17, 2026

UCI Health hosts Second Annual World UBE Society America Meeting

Spine experts from around the world gathered together for the Second Annual World UBE Society America Meeting.

UCI Health

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 07, 2026

Protein-First Policy Hits US Tables 

New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers

Conexiant

December 04, 2025

FDA Approves Biologic for Nerve Repair

A newly licensed biologic offers a novel approach to repairing complex peripheral nerve injuries across pediatric and adult populations.

Conexiant

December 02, 2025

Canine Tooth Embedded in Forearm After Bite

Radiographs revealed retained foreign body missed during physical examination, requiring surgical extraction.

Conexiant

November 25, 2025

FDA OKs First SMA Gene Replacement Therapy

The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.

Conexiant